SrasV1, PascalFrancis, Corpus, bibRecord, 000595

Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease

Identifieur interne : 000595 ( PascalFrancis/Corpus ); précédent : 000594; suivant : 000596

Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease

Auteurs : Jiun-Jie Shie ; Jim-Min Fang ; Chih-Jung Kuo ; Tun-Hsun Kuo ; Po-Huang Liang ; Hung-Jyun Huang ; Wen-Bin Yang ; Chun-Hung Lin ; Jiun-Ling Chen ; Yin-Ta Wu ; Chi-Huey Wong

Source :

Journal of medicinal chemistry : (Print) [ 0022-2623 ] ; 2005.

RBID : Pascal:05-0450262

Descripteurs français

Pascal (Inist)
- Anilide, Inhibiteur enzyme, Virus syndrome respiratoire aigu sévère, Peptidases, Antiviral, Peptide, Composé non peptide, Aminoamide, Benzène dérivé, Composé nitro, Relation structure activité, Tripeptide, Tétrapeptide, In vitro, Carboxamide, Phénylalanamide(N-[2-chloro-4-nitrophényl]-N-[4-(diméthylamino)benzoyl]).

English descriptors

KwdEn :
- Aminoamide, Anilide, Antiviral, Benzene derivatives, Carboxamide, Enzyme inhibitor, In vitro, Nitro compound, Non peptide compound, Peptidases, Peptides, Severe acute respiratory syndrome virus, Structure activity relation, Tetrapeptide, Tripeptide.

Abstract

A diversified library of peptide anilides was prepared, and their inhibition activities against the SARS-CoV 3CL protease were examined by a fluorogenic tetradecapeptide substrate. The most potent inhibitor is an anilide derived from 2-chloro-4-nitroaniline, L-phenylalanine and 4-(dimethylamino)benzoic acid. This anilide is a competitive inhibitor of the SARS-CoV 3CL protease with K_i = 0.03 μM. The molecular docking experiment indicates that the PI residue of this anilide inhibitor is distant from the nucleophilic SH of Cys145 in the active site.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0022-2623`
A02	`01`			`@0 JMCMAR`
A03		`1`		`@0 J. med. chem. : (Print)`
A05				`@2 48`
A06				`@2 13`
A08	`01`	`1`	`ENG`	`@1 Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease`
A11	`01`	`1`		`@1 SHIE (Jiun-Jie)`
A11	`02`	`1`		`@1 FANG (Jim-Min)`
A11	`03`	`1`		`@1 KUO (Chih-Jung)`
A11	`04`	`1`		`@1 KUO (Tun-Hsun)`
A11	`05`	`1`		`@1 LIANG (Po-Huang)`
A11	`06`	`1`		`@1 HUANG (Hung-Jyun)`
A11	`07`	`1`		`@1 YANG (Wen-Bin)`
A11	`08`	`1`		`@1 LIN (Chun-Hung)`
A11	`09`	`1`		`@1 CHEN (Jiun-Ling)`
A11	`10`	`1`		`@1 WU (Yin-Ta)`
A11	`11`	`1`		`@1 WONG (Chi-Huey)`
A14	`01`			`@1 Department of Chemistry, National Taiwan University @2 Taipei, 106 @3 TWN @Z 1 aut. @Z 2 aut. @Z 6 aut. @Z 9 aut.`
A14	`02`			`@1 Genomics Research Center, Academia Sinica @2 Taipei, 115 @3 TWN @Z 2 aut. @Z 7 aut. @Z 10 aut. @Z 11 aut.`
A14	`03`			`@1 Institute of Biological Chemistry, Academia Sinica @2 Taipei, 115 @3 TWN @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 8 aut.`
A14	`04`			`@1 Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute @2 La Jolla, California 92037 @3 USA @Z 11 aut.`
A20				`@1 4469-4473`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 9165 @5 354000138558210310`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 18 ref.`
A47	`01`	`1`		`@0 05-0450262`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of medicinal chemistry : (Print)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 A diversified library of peptide anilides was prepared, and their inhibition activities against the SARS-CoV 3CL protease were examined by a fluorogenic tetradecapeptide substrate. The most potent inhibitor is an anilide derived from 2-chloro-4-nitroaniline, L-phenylalanine and 4-(dimethylamino)benzoic acid. This anilide is a competitive inhibitor of the SARS-CoV 3CL protease with K_i = 0.03 μM. The molecular docking experiment indicates that the PI residue of this anilide inhibitor is distant from the nucleophilic SH of Cys145 in the active site.
C02	`01`	`X`		`@0 002B02S05`
C03	`01`	`X`	`FRE`	`@0 Anilide @5 01`
C03	`01`	`X`	`ENG`	`@0 Anilide @5 01`
C03	`01`	`X`	`SPA`	`@0 Anilido @5 01`
C03	`02`	`X`	`FRE`	`@0 Inhibiteur enzyme @5 02`
C03	`02`	`X`	`ENG`	`@0 Enzyme inhibitor @5 02`
C03	`02`	`X`	`SPA`	`@0 Inhibidor enzima @5 02`
C03	`03`	`X`	`FRE`	`@0 Virus syndrome respiratoire aigu sévère @2 NW @5 03`
C03	`03`	`X`	`ENG`	`@0 Severe acute respiratory syndrome virus @2 NW @5 03`
C03	`03`	`X`	`SPA`	`@0 Severe acute respiratory syndrome virus @2 NW @5 03`
C03	`04`	`X`	`FRE`	`@0 Peptidases @2 FE @5 04`
C03	`04`	`X`	`ENG`	`@0 Peptidases @2 FE @5 04`
C03	`04`	`X`	`SPA`	`@0 Peptidases @2 FE @5 04`
C03	`05`	`X`	`FRE`	`@0 Antiviral @5 05`
C03	`05`	`X`	`ENG`	`@0 Antiviral @5 05`
C03	`05`	`X`	`SPA`	`@0 Antiviral @5 05`
C03	`06`	`X`	`FRE`	`@0 Peptide @5 06`
C03	`06`	`X`	`ENG`	`@0 Peptides @5 06`
C03	`06`	`X`	`SPA`	`@0 Péptido @5 06`
C03	`07`	`X`	`FRE`	`@0 Composé non peptide @5 07`
C03	`07`	`X`	`ENG`	`@0 Non peptide compound @5 07`
C03	`07`	`X`	`SPA`	`@0 Compuesto no péptido @5 07`
C03	`08`	`X`	`FRE`	`@0 Aminoamide @5 08`
C03	`08`	`X`	`ENG`	`@0 Aminoamide @5 08`
C03	`08`	`X`	`SPA`	`@0 Aminoamida @5 08`
C03	`09`	`X`	`FRE`	`@0 Benzène dérivé @5 09`
C03	`09`	`X`	`ENG`	`@0 Benzene derivatives @5 09`
C03	`09`	`X`	`SPA`	`@0 Benceno derivado @5 09`
C03	`10`	`X`	`FRE`	`@0 Composé nitro @2 FX @5 11`
C03	`10`	`X`	`ENG`	`@0 Nitro compound @2 FX @5 11`
C03	`10`	`X`	`SPA`	`@0 Compuesto nitro @2 FX @5 11`
C03	`11`	`X`	`FRE`	`@0 Relation structure activité @5 12`
C03	`11`	`X`	`ENG`	`@0 Structure activity relation @5 12`
C03	`11`	`X`	`SPA`	`@0 Relación estructura actividad @5 12`
C03	`12`	`X`	`FRE`	`@0 Tripeptide @5 13`
C03	`12`	`X`	`ENG`	`@0 Tripeptide @5 13`
C03	`12`	`X`	`SPA`	`@0 Tripéptido @5 13`
C03	`13`	`X`	`FRE`	`@0 Tétrapeptide @5 14`
C03	`13`	`X`	`ENG`	`@0 Tetrapeptide @5 14`
C03	`13`	`X`	`SPA`	`@0 Tetrapéptido @5 14`
C03	`14`	`X`	`FRE`	`@0 In vitro @5 15`
C03	`14`	`X`	`ENG`	`@0 In vitro @5 15`
C03	`14`	`X`	`SPA`	`@0 In vitro @5 15`
C03	`15`	`X`	`FRE`	`@0 Carboxamide @5 32`
C03	`15`	`X`	`ENG`	`@0 Carboxamide @5 32`
C03	`15`	`X`	`SPA`	`@0 Carboxamida @5 32`
C03	`16`	`X`	`FRE`	`@0 Phénylalanamide(N-[2-chloro-4-nitrophényl]-N-[4-(diméthylamino)benzoyl]) @2 NK @2 FR @4 INC @5 76`
C07	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW`
C07	`02`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`05`	`X`	`FRE`	`@0 Hydrolases @2 FE`
C07	`05`	`X`	`ENG`	`@0 Hydrolases @2 FE`
C07	`05`	`X`	`SPA`	`@0 Hydrolases @2 FE`
C07	`06`	`X`	`FRE`	`@0 Enzyme @2 FE`
C07	`06`	`X`	`ENG`	`@0 Enzyme @2 FE`
C07	`06`	`X`	`SPA`	`@0 Enzima @2 FE`
C07	`07`	`X`	`FRE`	`@0 Chlore Composé organique @2 NC @2 FX @2 NA @5 10`
C07	`07`	`X`	`ENG`	`@0 Chlorine Organic compounds @2 NC @2 FX @2 NA @5 10`
C07	`07`	`X`	`SPA`	`@0 Cloro Compuesto orgánico @2 NC @2 FX @2 NA @5 10`
N21				`@1 318`

Format Inist (serveur)

NO :	PASCAL 05-0450262 INIST
ET :	Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease
AU :	SHIE (Jiun-Jie); FANG (Jim-Min); KUO (Chih-Jung); KUO (Tun-Hsun); LIANG (Po-Huang); HUANG (Hung-Jyun); YANG (Wen-Bin); LIN (Chun-Hung); CHEN (Jiun-Ling); WU (Yin-Ta); WONG (Chi-Huey)
AF :	Department of Chemistry, National Taiwan University/Taipei, 106/Taïwan (1 aut., 2 aut., 6 aut., 9 aut.); Genomics Research Center, Academia Sinica/Taipei, 115/Taïwan (2 aut., 7 aut., 10 aut., 11 aut.); Institute of Biological Chemistry, Academia Sinica/Taipei, 115/Taïwan (3 aut., 4 aut., 5 aut., 8 aut.); Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute/La Jolla, California 92037/Etats-Unis (11 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of medicinal chemistry : (Print); ISSN 0022-2623; Coden JMCMAR; Etats-Unis; Da. 2005; Vol. 48; No. 13; Pp. 4469-4473; Bibl. 18 ref.
LA :	Anglais
EA :	A diversified library of peptide anilides was prepared, and their inhibition activities against the SARS-CoV 3CL protease were examined by a fluorogenic tetradecapeptide substrate. The most potent inhibitor is an anilide derived from 2-chloro-4-nitroaniline, L-phenylalanine and 4-(dimethylamino)benzoic acid. This anilide is a competitive inhibitor of the SARS-CoV 3CL protease with K_i = 0.03 μM. The molecular docking experiment indicates that the PI residue of this anilide inhibitor is distant from the nucleophilic SH of Cys145 in the active site.
CC :	002B02S05
FD :	Anilide; Inhibiteur enzyme; Virus syndrome respiratoire aigu sévère; Peptidases; Antiviral; Peptide; Composé non peptide; Aminoamide; Benzène dérivé; Composé nitro; Relation structure activité; Tripeptide; Tétrapeptide; In vitro; Carboxamide; Phénylalanamide(N-[2-chloro-4-nitrophényl]-N-[4-(diméthylamino)benzoyl])
FG :	Coronavirus; Coronaviridae; Nidovirales; Virus; Hydrolases; Enzyme; Chlore Composé organique
ED :	Anilide; Enzyme inhibitor; Severe acute respiratory syndrome virus; Peptidases; Antiviral; Peptides; Non peptide compound; Aminoamide; Benzene derivatives; Nitro compound; Structure activity relation; Tripeptide; Tetrapeptide; In vitro; Carboxamide
EG :	Coronavirus; Coronaviridae; Nidovirales; Virus; Hydrolases; Enzyme; Chlorine Organic compounds
SD :	Anilido; Inhibidor enzima; Severe acute respiratory syndrome virus; Peptidases; Antiviral; Péptido; Compuesto no péptido; Aminoamida; Benceno derivado; Compuesto nitro; Relación estructura actividad; Tripéptido; Tetrapéptido; In vitro; Carboxamida
LO :	INIST-9165.354000138558210310
ID :	05-0450262

Links to Exploration step

Pascal:05-0450262

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease</title>
<author><name sortKey="Shie, Jiun Jie" sort="Shie, Jiun Jie" uniqKey="Shie J" first="Jiun-Jie" last="Shie">Jiun-Jie Shie</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Chemistry, National Taiwan University</s1>
<s2>Taipei, 106</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fang, Jim Min" sort="Fang, Jim Min" uniqKey="Fang J" first="Jim-Min" last="Fang">Jim-Min Fang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Chemistry, National Taiwan University</s1>
<s2>Taipei, 106</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Genomics Research Center, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kuo, Chih Jung" sort="Kuo, Chih Jung" uniqKey="Kuo C" first="Chih-Jung" last="Kuo">Chih-Jung Kuo</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Biological Chemistry, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kuo, Tun Hsun" sort="Kuo, Tun Hsun" uniqKey="Kuo T" first="Tun-Hsun" last="Kuo">Tun-Hsun Kuo</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Biological Chemistry, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Liang, Po Huang" sort="Liang, Po Huang" uniqKey="Liang P" first="Po-Huang" last="Liang">Po-Huang Liang</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Biological Chemistry, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Huang, Hung Jyun" sort="Huang, Hung Jyun" uniqKey="Huang H" first="Hung-Jyun" last="Huang">Hung-Jyun Huang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Chemistry, National Taiwan University</s1>
<s2>Taipei, 106</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yang, Wen Bin" sort="Yang, Wen Bin" uniqKey="Yang W" first="Wen-Bin" last="Yang">Wen-Bin Yang</name>
<affiliation><inist:fA14 i1="02"><s1>Genomics Research Center, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lin, Chun Hung" sort="Lin, Chun Hung" uniqKey="Lin C" first="Chun-Hung" last="Lin">Chun-Hung Lin</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Biological Chemistry, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chen, Jiun Ling" sort="Chen, Jiun Ling" uniqKey="Chen J" first="Jiun-Ling" last="Chen">Jiun-Ling Chen</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Chemistry, National Taiwan University</s1>
<s2>Taipei, 106</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wu, Yin Ta" sort="Wu, Yin Ta" uniqKey="Wu Y" first="Yin-Ta" last="Wu">Yin-Ta Wu</name>
<affiliation><inist:fA14 i1="02"><s1>Genomics Research Center, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wong, Chi Huey" sort="Wong, Chi Huey" uniqKey="Wong C" first="Chi-Huey" last="Wong">Chi-Huey Wong</name>
<affiliation><inist:fA14 i1="02"><s1>Genomics Research Center, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute</s1>
<s2>La Jolla, California 92037</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0450262</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0450262 INIST</idno>
<idno type="RBID">Pascal:05-0450262</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000595</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease</title>
<author><name sortKey="Shie, Jiun Jie" sort="Shie, Jiun Jie" uniqKey="Shie J" first="Jiun-Jie" last="Shie">Jiun-Jie Shie</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Chemistry, National Taiwan University</s1>
<s2>Taipei, 106</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fang, Jim Min" sort="Fang, Jim Min" uniqKey="Fang J" first="Jim-Min" last="Fang">Jim-Min Fang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Chemistry, National Taiwan University</s1>
<s2>Taipei, 106</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Genomics Research Center, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kuo, Chih Jung" sort="Kuo, Chih Jung" uniqKey="Kuo C" first="Chih-Jung" last="Kuo">Chih-Jung Kuo</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Biological Chemistry, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kuo, Tun Hsun" sort="Kuo, Tun Hsun" uniqKey="Kuo T" first="Tun-Hsun" last="Kuo">Tun-Hsun Kuo</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Biological Chemistry, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Liang, Po Huang" sort="Liang, Po Huang" uniqKey="Liang P" first="Po-Huang" last="Liang">Po-Huang Liang</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Biological Chemistry, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Huang, Hung Jyun" sort="Huang, Hung Jyun" uniqKey="Huang H" first="Hung-Jyun" last="Huang">Hung-Jyun Huang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Chemistry, National Taiwan University</s1>
<s2>Taipei, 106</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yang, Wen Bin" sort="Yang, Wen Bin" uniqKey="Yang W" first="Wen-Bin" last="Yang">Wen-Bin Yang</name>
<affiliation><inist:fA14 i1="02"><s1>Genomics Research Center, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lin, Chun Hung" sort="Lin, Chun Hung" uniqKey="Lin C" first="Chun-Hung" last="Lin">Chun-Hung Lin</name>
<affiliation><inist:fA14 i1="03"><s1>Institute of Biological Chemistry, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chen, Jiun Ling" sort="Chen, Jiun Ling" uniqKey="Chen J" first="Jiun-Ling" last="Chen">Jiun-Ling Chen</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Chemistry, National Taiwan University</s1>
<s2>Taipei, 106</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wu, Yin Ta" sort="Wu, Yin Ta" uniqKey="Wu Y" first="Yin-Ta" last="Wu">Yin-Ta Wu</name>
<affiliation><inist:fA14 i1="02"><s1>Genomics Research Center, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wong, Chi Huey" sort="Wong, Chi Huey" uniqKey="Wong C" first="Chi-Huey" last="Wong">Chi-Huey Wong</name>
<affiliation><inist:fA14 i1="02"><s1>Genomics Research Center, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute</s1>
<s2>La Jolla, California 92037</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of medicinal chemistry : (Print)</title>
<title level="j" type="abbreviated">J. med. chem. : (Print)</title>
<idno type="ISSN">0022-2623</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of medicinal chemistry : (Print)</title>
<title level="j" type="abbreviated">J. med. chem. : (Print)</title>
<idno type="ISSN">0022-2623</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aminoamide</term>
<term>Anilide</term>
<term>Antiviral</term>
<term>Benzene derivatives</term>
<term>Carboxamide</term>
<term>Enzyme inhibitor</term>
<term>In vitro</term>
<term>Nitro compound</term>
<term>Non peptide compound</term>
<term>Peptidases</term>
<term>Peptides</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Structure activity relation</term>
<term>Tetrapeptide</term>
<term>Tripeptide</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Anilide</term>
<term>Inhibiteur enzyme</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Peptidases</term>
<term>Antiviral</term>
<term>Peptide</term>
<term>Composé non peptide</term>
<term>Aminoamide</term>
<term>Benzène dérivé</term>
<term>Composé nitro</term>
<term>Relation structure activité</term>
<term>Tripeptide</term>
<term>Tétrapeptide</term>
<term>In vitro</term>
<term>Carboxamide</term>
<term>Phénylalanamide(N-[2-chloro-4-nitrophényl]-N-[4-(diméthylamino)benzoyl])</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A diversified library of peptide anilides was prepared, and their inhibition activities against the SARS-CoV 3CL protease were examined by a fluorogenic tetradecapeptide substrate. The most potent inhibitor is an anilide derived from 2-chloro-4-nitroaniline, L-phenylalanine and 4-(dimethylamino)benzoic acid. This anilide is a competitive inhibitor of the SARS-CoV 3CL protease with K<sub>i</sub>
 = 0.03 μM. The molecular docking experiment indicates that the PI residue of this anilide inhibitor is distant from the nucleophilic SH of Cys145 in the active site.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-2623</s0>
</fA01>
<fA02 i1="01"><s0>JMCMAR</s0>
</fA02>
<fA03 i2="1"><s0>J. med. chem. : (Print)</s0>
</fA03>
<fA05><s2>48</s2>
</fA05>
<fA06><s2>13</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SHIE (Jiun-Jie)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FANG (Jim-Min)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KUO (Chih-Jung)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>KUO (Tun-Hsun)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LIANG (Po-Huang)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>HUANG (Hung-Jyun)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>YANG (Wen-Bin)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>LIN (Chun-Hung)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>CHEN (Jiun-Ling)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>WU (Yin-Ta)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>WONG (Chi-Huey)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Chemistry, National Taiwan University</s1>
<s2>Taipei, 106</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Genomics Research Center, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Institute of Biological Chemistry, Academia Sinica</s1>
<s2>Taipei, 115</s2>
<s3>TWN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute</s1>
<s2>La Jolla, California 92037</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA20><s1>4469-4473</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>9165</s2>
<s5>354000138558210310</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>18 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0450262</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of medicinal chemistry : (Print)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A diversified library of peptide anilides was prepared, and their inhibition activities against the SARS-CoV 3CL protease were examined by a fluorogenic tetradecapeptide substrate. The most potent inhibitor is an anilide derived from 2-chloro-4-nitroaniline, L-phenylalanine and 4-(dimethylamino)benzoic acid. This anilide is a competitive inhibitor of the SARS-CoV 3CL protease with K<sub>i</sub>
 = 0.03 μM. The molecular docking experiment indicates that the PI residue of this anilide inhibitor is distant from the nucleophilic SH of Cys145 in the active site.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Anilide</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Anilide</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Anilido</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Peptide</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Peptides</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Péptido</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Composé non peptide</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Non peptide compound</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Compuesto no péptido</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Aminoamide</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Aminoamide</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Aminoamida</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Benzène dérivé</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Benzene derivatives</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Benceno derivado</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Composé nitro</s0>
<s2>FX</s2>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Nitro compound</s0>
<s2>FX</s2>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Compuesto nitro</s0>
<s2>FX</s2>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Relation structure activité</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Structure activity relation</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Relación estructura actividad</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Tripeptide</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Tripeptide</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Tripéptido</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Tétrapeptide</s0>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Tetrapeptide</s0>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Tetrapéptido</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>In vitro</s0>
<s5>15</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>In vitro</s0>
<s5>15</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>In vitro</s0>
<s5>15</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Carboxamide</s0>
<s5>32</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Carboxamide</s0>
<s5>32</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Carboxamida</s0>
<s5>32</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Phénylalanamide(N-[2-chloro-4-nitrophényl]-N-[4-(diméthylamino)benzoyl])</s0>
<s2>NK</s2>
<s2>FR</s2>
<s4>INC</s4>
<s5>76</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Chlore Composé organique</s0>
<s2>NC</s2>
<s2>FX</s2>
<s2>NA</s2>
<s5>10</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Chlorine Organic compounds</s0>
<s2>NC</s2>
<s2>FX</s2>
<s2>NA</s2>
<s5>10</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Cloro Compuesto orgánico</s0>
<s2>NC</s2>
<s2>FX</s2>
<s2>NA</s2>
<s5>10</s5>
</fC07>
<fN21><s1>318</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 05-0450262 INIST</NO>
<ET>Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease</ET>
<AU>SHIE (Jiun-Jie); FANG (Jim-Min); KUO (Chih-Jung); KUO (Tun-Hsun); LIANG (Po-Huang); HUANG (Hung-Jyun); YANG (Wen-Bin); LIN (Chun-Hung); CHEN (Jiun-Ling); WU (Yin-Ta); WONG (Chi-Huey)</AU>
<AF>Department of Chemistry, National Taiwan University/Taipei, 106/Taïwan (1 aut., 2 aut., 6 aut., 9 aut.); Genomics Research Center, Academia Sinica/Taipei, 115/Taïwan (2 aut., 7 aut., 10 aut., 11 aut.); Institute of Biological Chemistry, Academia Sinica/Taipei, 115/Taïwan (3 aut., 4 aut., 5 aut., 8 aut.); Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute/La Jolla, California 92037/Etats-Unis (11 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of medicinal chemistry : (Print); ISSN 0022-2623; Coden JMCMAR; Etats-Unis; Da. 2005; Vol. 48; No. 13; Pp. 4469-4473; Bibl. 18 ref.</SO>
<LA>Anglais</LA>
<EA>A diversified library of peptide anilides was prepared, and their inhibition activities against the SARS-CoV 3CL protease were examined by a fluorogenic tetradecapeptide substrate. The most potent inhibitor is an anilide derived from 2-chloro-4-nitroaniline, L-phenylalanine and 4-(dimethylamino)benzoic acid. This anilide is a competitive inhibitor of the SARS-CoV 3CL protease with K<sub>i</sub>
 = 0.03 μM. The molecular docking experiment indicates that the PI residue of this anilide inhibitor is distant from the nucleophilic SH of Cys145 in the active site.</EA>
<CC>002B02S05</CC>
<FD>Anilide; Inhibiteur enzyme; Virus syndrome respiratoire aigu sévère; Peptidases; Antiviral; Peptide; Composé non peptide; Aminoamide; Benzène dérivé; Composé nitro; Relation structure activité; Tripeptide; Tétrapeptide; In vitro; Carboxamide; Phénylalanamide(N-[2-chloro-4-nitrophényl]-N-[4-(diméthylamino)benzoyl])</FD>
<FG>Coronavirus; Coronaviridae; Nidovirales; Virus; Hydrolases; Enzyme; Chlore Composé organique</FG>
<ED>Anilide; Enzyme inhibitor; Severe acute respiratory syndrome virus; Peptidases; Antiviral; Peptides; Non peptide compound; Aminoamide; Benzene derivatives; Nitro compound; Structure activity relation; Tripeptide; Tetrapeptide; In vitro; Carboxamide</ED>
<EG>Coronavirus; Coronaviridae; Nidovirales; Virus; Hydrolases; Enzyme; Chlorine Organic compounds</EG>
<SD>Anilido; Inhibidor enzima; Severe acute respiratory syndrome virus; Peptidases; Antiviral; Péptido; Compuesto no péptido; Aminoamida; Benceno derivado; Compuesto nitro; Relación estructura actividad; Tripéptido; Tetrapéptido; In vitro; Carboxamida</SD>
<LO>INIST-9165.354000138558210310</LO>
<ID>05-0450262</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000595 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000595 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:05-0450262
   |texte=   Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease

Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri